Building an AI-Native Research Site From the First Patient Onward

Between 2024 and 2026, three regulatory developments moved artificial intelligence in clinical research from an interesting experiment to an institutionally legitimate part of the drug development lifecycle: joint FDA and EMA guiding principles for Good AI Practice, the EMA's qualification of a digital-twin methodology for pivotal trial sample-size reduction, and the FDA's Real-Time Clinical Trials pilot program.

Most sites are responding by layering AI tools onto operations that were designed a decade or more ago — legacy CTMS platforms, paper-adjacent source documentation, and monitoring workflows built for a pre-LLM world. Mount Clinical Research took a different starting position: because our site was established in 2026, every SOP, source document, and monitoring workflow was designed with AI-assisted review built in from the first patient.

That distinction matters more than it sounds. Sponsors and CROs are increasingly scoring sites not just on historical enrollment velocity, but on the machine-readability of their performance data, the auditability of their AI-assisted workflows, and their ability to participate in emerging paradigms like real-time endpoint streaming. A site that has to retrofit its data infrastructure to participate is starting months behind a site that was built for it.

Our own FlowAutoGate™ platform, developed with Rio Eigen AI, is a concrete example: automated flow cytometry gating in under 30 seconds per million events, with greater than 95% concordance to expert manual analysis. That is not a bolt-on feature — it is the standard workflow our bioanalytical laboratory runs on every immunogenicity sample, with a complete 21 CFR Part 11-compliant audit trail attached to every result.

Every AI workflow we operate has a named human reviewer. We view explainability and human oversight as a prerequisite for participating responsibly in this shift, not an obstacle to it. As real-time trials and AI-assisted feasibility scoring become standard sponsor expectations over the next several years, we believe the sites that built this infrastructure early will be the reference points everyone else is measured against.